Clinical Research Directory

Inclusion Criteria: * Patient over 18 years * Symptomatology of angina pectoris * Receiving invasive coronary angiography * FFR and microcirculatory resistance index (MRI) measurement for at least one epicardial lesion ≥ 50% : * For lesions with FFR ≤ 0.8, revascularization with the XIENCE Sierra stent and its evolutions will be performed. Optimization of this epicardial revascularization will be evidenced by a post-PCI FFR \> 0.8 on all major trunks and if an FFR measurement is not performed, absence of 50% or greater stenosis on two orthogonal views by quantitative coronary angiography \[QCA\] at the revascularization site. * For lesions with FFR \> 0.8 revascularization will not be performed * Written informed consent Exclusion Criteria: * A non-coronary indication for coronary angiography, e.g. valve disease, hypertrophic obstructive cardiomyopathy. * Severe renal dysfunction (GFR \< 30 ml/min) * Contraindications for adenosine: asthma, Second or third degree AV block without pacemaker or sick sinus syndrome, Systolic blood pressure less than 90 mm Hg, Recent use of dipyridamole or drugs containing dipyridamole, Methyl xanthenes such as caffeine aminophylline or theobromine block the effect of adenosine and should be stored at least 12 hours before testing, Known hypersensitivity to adenosine. * Pregnant women, parturients and breastfeeding mothers * Persons of full age who are subject to a legal protection measure or who are unable to express their consent * Patient in a period of exclusion from another study * Patient under administrative or judicial supervision